| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/16/2002 | CN1331701A Modified peptides as therapeutic agents |
| 01/16/2002 | CN1331692A Benzisozazoles and phenones as alpha antagonist |
| 01/16/2002 | CN1331688A Aminopyrazole derivatives |
| 01/16/2002 | CN1331683A 2-phenylbenzimidazoles and 2-phenylindoles, and prodn. and use thereof |
| 01/16/2002 | CN1331682A Substituted 2-phenylbenzimidazoles, prodn. thereof and their use |
| 01/16/2002 | CN1331597A Use of bisphosphonates for prevention and treatment of infectious processes |
| 01/16/2002 | CN1330955A Instant particles for regulating growth and trace element absorption of human bone |
| 01/16/2002 | CN1330948A Prescription for losing weight without recurrence |
| 01/16/2002 | CN1330941A Weight losing tea |
| 01/16/2002 | CN1077886C Amidino derivatives useful as nitric oxide synthase inhibitors |
| 01/16/2002 | CN1077792C Pyridylbisphosphonates for use as therapeutical agent |
| 01/15/2002 | US6339106 Methods and compositions for the treatment and prevention of sexual dysfunction |
| 01/15/2002 | US6339097 N-phenylamide and N-pyridylamide derivatives, method of preparing them and pharmaceutical compositions containing them |
| 01/15/2002 | US6339085 For therapy of hypertrophy, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, heart failure subsequent to myocardial infarction, myocardial infarction, ischemia reperfusion injury, blood coagulation |
| 01/15/2002 | US6339077 Substituted 4-benzylaminoquinolines and their hetero analogs, process for their preparation, pharmaceuticals containing these compounds and use thereof |
| 01/15/2002 | US6338850 Administering immunosuppressive dosage of plant tissue and purification |
| 01/15/2002 | US6338848 Treating multiple sclerosis with immunoglobulins and interleukins |
| 01/15/2002 | CA2067243C Compositions and methods for weight reduction |
| 01/15/2002 | CA2054209C Antihyperlipidemic and antiatherosclerotic urea compounds |
| 01/10/2002 | WO2002002797A2 Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme |
| 01/10/2002 | WO2002002770A1 Novel g protein-coupled receptor protein and dna thereof |
| 01/10/2002 | WO2002002767A1 Novel g protein-coupled receptor protein and dna thereof |
| 01/10/2002 | WO2002002756A2 Glycosylphosphatidylinositol specific phospholipase d proteins for the treatment or diagnosis of atherosclerosis |
| 01/10/2002 | WO2002002744A2 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
| 01/10/2002 | WO2002002645A1 COLD WATER SOLUBLE β-GLUCAN PRODUCT AND PROCESS FOR PREPARING THE SAME |
| 01/10/2002 | WO2002002640A2 Antibodies to human mcp-1 |
| 01/10/2002 | WO2002002638A2 Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| 01/10/2002 | WO2002002634A2 Human extracellular matrix and cell adhesion polypeptides |
| 01/10/2002 | WO2002002633A2 Transporters and ion channels |
| 01/10/2002 | WO2002002625A2 Novel fibroblast growth factors and nucleic acids encoding same |
| 01/10/2002 | WO2002002603A2 Protein modification and maintenance molecules |
| 01/10/2002 | WO2002002587A1 B7-like polynucleotides, polypeptides, and antibodies |
| 01/10/2002 | WO2002002583A1 Amine salt of lignan compound |
| 01/10/2002 | WO2002002564A1 Aryl and heteroaryl diazabicycloalkanes, their preparation and use |
| 01/10/2002 | WO2002002560A2 Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv) |
| 01/10/2002 | WO2002002554A1 Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders |
| 01/10/2002 | WO2002002553A1 Pharmaceutical compositions for treatment of diabetic nephropathy |
| 01/10/2002 | WO2002002551A1 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| 01/10/2002 | WO2002002541A2 Inhibitors of copper-containing amine oxidases |
| 01/10/2002 | WO2002002517A1 Acylsulfonamide derivatives |
| 01/10/2002 | WO2002002179A1 Microneedle for delivering a substance into the dermis |
| 01/10/2002 | WO2002002178A1 Needle for intradermal delivery of substances having penetration limiting means |
| 01/10/2002 | WO2002002136A1 Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components |
| 01/10/2002 | WO2002002128A2 Oral compositions comprising antimicrobial agents |
| 01/10/2002 | WO2002002106A1 Use of modified tall oil in combination with dietary supplements to improve body composition and health status |
| 01/10/2002 | WO2002002105A1 Therapeutic combinations of fatty acids |
| 01/10/2002 | WO2002002102A1 Rapid fatty acid delivery |
| 01/10/2002 | WO2002002101A1 Hypoglycemics |
| 01/10/2002 | WO2002002100A1 Remedies for diabetes |
| 01/10/2002 | WO2002002096A2 Oral compositions comprising host-response modulating agent |
| 01/10/2002 | WO2002002090A2 Inhibitors of copper-containing amine oxidases |
| 01/10/2002 | WO2002001969A1 Vitamin k and essential fatty acids |
| 01/10/2002 | WO2001094636A8 Compositions, kits, and methods for identification and modulation of type i diabetes |
| 01/10/2002 | WO2001070709A3 3-oxy-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadazine-1,1-dioxide derivatives having diuretic and/or natriuretic activity |
| 01/10/2002 | WO2001059071A3 Methods of preparing and using a viral vector library |
| 01/10/2002 | WO2001056993A3 Pyrazole compositions useful as inhibitors of erk |
| 01/10/2002 | WO2001048483A3 Method for screening of appetite control agents |
| 01/10/2002 | WO2001043762A3 Polypeptide compositions with improved stability |
| 01/10/2002 | WO2001043691A3 Fragments and antagonists of heat shock protein 60 |
| 01/10/2002 | WO2001038344A3 Modulation of signal transduction |
| 01/10/2002 | WO2001036425A3 Imidazole compounds used as phosphodiesterase vii inhibitors |
| 01/10/2002 | WO2001034604A3 Adenosine receptor antagonists and methods of making and using the same |
| 01/10/2002 | WO2001032616A3 Oxetanone derivatives |
| 01/10/2002 | WO2001026641A3 Morpholinol derivatives for the treatment of obesity |
| 01/10/2002 | WO2000061138A8 Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders |
| 01/10/2002 | WO2000055332A3 Human regulators of intracellular phosphorylation |
| 01/10/2002 | US20020004585 Antibody for use in the detection of preferential enzyme expression; for use as tool in treatment and detection of enzyme defects; for treatment autoimmune disease, inflammation, sepsis, diabetes, kidney defects and cancer |
| 01/10/2002 | US20020004520 Crystalline(-)-3r,4r-trans-7methoxy-2,2-dimethyl-3-phenyl-4-{4-[2- (pyrrolidin-1-yl)ethoxy]pheny 1}chromane, hydrogen malete |
| 01/10/2002 | US20020004513 Azacyclic compounds |
| 01/10/2002 | US20020004512 Sexual disorders |
| 01/10/2002 | US20020004501 Therapy for muscular disorders, urogenital disorders, gastrointestinal disorders, respiratory system disorders |
| 01/10/2002 | US20020004049 Tryptophan source from plants and uses therfor |
| 01/10/2002 | DE10019714A1 Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen Salts of bicyclic, N-acylated imidazo-3-amines and imidazo-5-amines |
| 01/10/2002 | CA2630062A1 Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule |
| 01/10/2002 | CA2415123A1 Novel fibroblast growth factors and nucleic acids encoding same |
| 01/10/2002 | CA2414966A1 A pharmaceutical component based on human parathyroid hormone and a pharmaceutical composition for intranasal administration containing the component |
| 01/10/2002 | CA2414807A1 Inhibitors of copper-containing amine oxidases |
| 01/10/2002 | CA2414799A1 Inhibitors of copper-containing amine oxidases |
| 01/10/2002 | CA2414468A1 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| 01/10/2002 | CA2414375A1 Glycosylphosphatidylinositol specific phospholipase d proteins for the treatment or diagnosis of atherosclerosis |
| 01/10/2002 | CA2413243A1 Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders |
| 01/10/2002 | CA2413186A1 Extracellular matrix and cell adhesion molecules |
| 01/10/2002 | CA2413128A1 Transporters and ion channels |
| 01/10/2002 | CA2412872A1 Protein modification and maintenance molecules |
| 01/10/2002 | CA2412775A1 Antibodies to human mcp-1 |
| 01/10/2002 | CA2412620A1 Vitamin k and essential fatty acids |
| 01/10/2002 | CA2411864A1 Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv) |
| 01/10/2002 | CA2410945A1 Aryl and heteroaryl diazabicycloalkanes, their preparation and use |
| 01/10/2002 | CA2406649A1 B7-like polynucleotides, polypeptides, and antibodies |
| 01/09/2002 | EP1170007A1 Remedies |
| 01/09/2002 | EP1169475A1 Diagnosis of a person's risk for developing atherosclerosis or diabetic retinopathy |
| 01/09/2002 | EP1169459A1 Dsp-9 dual-specificity map kinase phosphatase |
| 01/09/2002 | EP1169451A2 Nucleic acids coding for novel truncated cart proteins, corresponding truncated cart polypeptides and their use for therapeutic and diagnostic purposes |
| 01/09/2002 | EP1169448A1 Tumor necrosis factor homologs and nucleic acids encoding the same |
| 01/09/2002 | EP1169442A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 01/09/2002 | EP1169440A1 48 human secreted proteins |
| 01/09/2002 | EP1169350A2 Human obesity protein binding protein-2 homolog compositions and uses thereof |
| 01/09/2002 | EP1169348A1 Purposeful movement of human migratory cells away from an agent source |
| 01/09/2002 | EP1169333A1 49 human secreted proteins |
| 01/09/2002 | EP1169322A1 Pyridoxal analogues for vitamin b-6 disorders |